Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05374148
Other study ID # Respiratory ferrosilicon
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date October 1, 2023

Study information

Verified date May 2022
Source Assiut University
Contact Alaa Bazied, B.C.C.H
Phone +201155836349
Email ala2238972@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To minimize the negative effects of exposure to silica, iron chips, and coke on the respiratory health of workers in the Ferro alloy factory, so it is important to assess and diagnose their health-related effects. Early reporting, diagnosis, and intervention can limit the severity of health hazards, improve health services. To our knowledge, no local previous studies were done in this area. All over the world there is no sufficient information relating to this industry and its health hazards.


Description:

Ferrosilicon alloy is a mixture of iron and silicon. It's added to steel and cast iron. By oxidation of the iron, it offers superior properties to iron such as high strength, hardness, and resistance to corrosion and high temperatures. Around 90% of ferrosilicon alloys is consumed in the production of iron and steel. Silica dust is a secondary product of ferrosilicon industry. Its addition to concrete improve its chemical and physical properties[1] . Ferrosilicon is an alloy of iron and silicon with high silicon content. Ferrosilicon alloys are produced in electric arc furnaces. At very high temperatures (2000°C). These furnaces are charged with quartz which is the main source of silica, iron chips, and coke which is used as a reducing agent. The industry process produces very fine particles of amorphous silica (SiO 2) powder(fume). The composition of the fumes varies somewhat according to which alloy is produced. In the production of ferrosilicon alloy with a high silicon content, the amount of Si02 in the fumes can be 80% or more[2]. Workers in the ferroalloy industry have been exposed to a variety of gases, fumes, and dust that may adversely affect the respiratory system. Among employees in Ferrosilicon plants, there is an increase in mortality rate from bronchitis, emphysema, and asthma[3]. Occupational exposure to respirable crystalline silica (SiO2) is one of the most common and serious hazards. It is considered a serious hazard for the ferrosilicon industry. Silicosis is the disease most associated with crystalline silica exposure. It causes by the inhalation of respirable crystalline silica dust [4]. It is a fibrotic lung disease progressive, irreversible, [5]. It is incurable but preventable[6]. Chronic Silicosis occurs due to the prolonged inhalation of respirable crystalline silica dust [4]. The major risk factors for developing silicosis include cumulative lifetime exposure, the total amount of inhaled crystalline Silica, silica size(0.5-3 µ) and individual susceptibility [6]. Thus, making silica dust one of the greater public health problems. Silicosis is considered one of the most serious occupational diseases in the world. According to many previous studies, a large number of workers are exposed to silica dust throughout the world. At least 3.2 million workers in Europe and more than 2 million in the United States are exposed to silica dust[4] . In Asia, the prevalence of silicosis is up to 55% among workers exposed to silica dust, while in Latin America, the prevalence is up to 37%[8] In Egypt ,the prevalence rate of silicosis ranges from 18.5 % to 45.8% among workers exposed to free crystalline silica dust[9] Although many studies illustrated the relationship between silica exposure and silicosis occurrence in a different industries , there are no sufficient studies relating to the ferrosilicon industry and its respiratory hazards.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 250
Est. completion date October 1, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Active working miners working in ferrosilicon alloy factory with minimum exposure 5 years. - Workers exposed to silica, iron chips, and coke in quarry and Furnaces areas. - Have free pre-employment records especially free chest x-rays. have no previous pre- employment history of any chest problems. Exclusion Criteria: - • Workers don't record silica, iron chips, and coke exposer as in the administration department. - Workers with less than 5-year exposure. - Workers are known to have chest diseases before joining the work for example emphysema and COPD.

Study Design


Intervention

Behavioral:
health education
health education to prevent respiratory diseases among workers

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (2)

Kalliny MS, Bassyouni MI. Immune response due to silica exposure in Egyptian phosphate mines. J Health Care Poor Underserved. 2011;22(4 Suppl):91-109. doi: 10.1353/hpu.2011.0156. — View Citation

Leung CC, Yu IT, Chen W. Silicosis. Lancet. 2012 May 26;379(9830):2008-18. doi: 10.1016/S0140-6736(12)60235-9. Epub 2012 Apr 24. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary prevalence prevalence of silicosis among ferrosilicon industry workers. 1 year
See also
  Status Clinical Trial Phase
Withdrawn NCT03376204 - Pain Mechanisms in Patients With Bronchiectasis
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Recruiting NCT05246098 - REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI
Completed NCT04467190 - Investigation of Inflammacheck to Measure Exhaled Breath Condensate Hydrogen Peroxide in Respiratory Conditions
Recruiting NCT04502368 - Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients
Recruiting NCT05775952 - Airway Remodeling and Rhinovirus in Asthmatics
Active, not recruiting NCT02681848 - What Are the Effects of Varenicline Compared With Nicotine Replacement Therapy on Long Term Smoking Cessation and Clinically Important Outcomes?
Recruiting NCT06002685 - Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention N/A
Enrolling by invitation NCT03319446 - Collection of Anonymized Samples N/A
Recruiting NCT04287959 - SWISH Trial (Strategies for Weaning Infants on Supportive High Flow) N/A
Completed NCT05017727 - Closed-loop Oxygen Control in Ventilated Infants Born at or Near Term
Completed NCT04607330 - Protein Top-up Acceptability Study for Patients With Increased Protein Needs N/A
Completed NCT03334916 - A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients Phase 4
Completed NCT04649736 - Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients N/A
Completed NCT03661801 - Novel Pleural Fluid, Biopsy and Serum Biomarkers for the Investigation of Pleural Effusions
Enrolling by invitation NCT03322254 - How Respiratory Pathogens Panel Results Affect Patients' Plan of Care
Recruiting NCT03937583 - Screening for Cancer in Patients With Unprovoked VTE Phase 4
Not yet recruiting NCT06026163 - Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress Phase 2/Phase 3
Completed NCT04581096 - Mapping COVID-19 Spread in a Tertiary Hospital
Completed NCT03654092 - Home-based Exercise Training for COPD Patients (HOMEX-2) N/A